Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
14.00
+0.32 (2.34%)
Sep 18, 2024, 2:55 PM EDT - Market open
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $36.84M in the quarter ending June 30, 2024, with 42.32% growth. This brings the company's revenue in the last twelve months to $130.20M, up 7.48% year-over-year. In the year 2023, Rigel Pharmaceuticals had annual revenue of $115.78M with 0.03% growth.
Revenue (ttm)
$130.20M
Revenue Growth
+7.48%
P/S Ratio
1.84
Revenue / Employee
$885,721
Employees
147
Market Cap
246.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 115.78M | 40.00K | 0.03% |
Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 264.78M |
Enanta Pharmaceuticals | 71.96M |
Zenas BioPharma | 50.00M |
Utah Medical Products | 46.58M |
2seventy bio | 44.12M |
Alpha Teknova | 34.94M |
Mersana Therapeutics | 29.94M |
Artiva Biotherapeutics | 29.26M |
RIGL News
- 6 days ago - Rigel to Present at the 2024 Cantor Global Healthcare Conference - PRNewsWire
- 13 days ago - Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML - PRNewsWire
- 15 days ago - Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan - PRNewsWire
- 20 days ago - Rigel to Participate in Upcoming September Investor Conferences - PRNewsWire
- 5 weeks ago - Rigel Pharmaceuticals, Inc. (RIGL) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 7 weeks ago - Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential - Seeking Alpha